## Status: Awaiting Hypotheses & Evidence
I notice a critical gap in your request:
### What You've Provided
- A research gap ("therapeutic window between GCS inhibition efficacy and systemic toxicity")
- Search query strings (formatted as unexecuted tool calls)
- "I'll research this systematically to generate grounded hypotheses" — **but no actual hypotheses have been generated**
### What I Need to Evaluate
For me to perform rigorous hypothesis critique, you must provide:
| Required Element | Description |
|------------------|-------------|
| **Specific hypotheses** | Clear, falsifiable statements (e.g., "A 50% reduction in GCS activity is the optimal therapeutic threshold...") |
| **Supporting evidence** | Real data from studies you've retrieved |
| **Proposed mechanism** | How GCS inhibition is hypothesized to work in GBA-PD |
| **Toxicity thresholds** | What preclinical/clinical evidence exists for toxicity windows |
### To Move Forward
Please execute your searches and provide:
1. **Key findings from the literature** on GCS inhibitors (eliglustat, venglustat, GZ/SAR402671) in PD or related models
2. **Specific therapeutic window hypotheses** you want evaluated
3. **Evidence for both efficacy AND toxicity endpoints**
### Note on the Literature
Based on my training knowledge, several relevant findings exist:
- GZ/SAR402671 (Genzyme/Sanofi) was discontinued due to **CNS toxicity** in a higher-dose cohort — directly relevant to your therapeutic window question
- Eliglustat (Cerdelga) has FDA approval for Gaucher disease type 1 but shows **limited CNS penetration**
- Preclinical studies in GBA-PD models show substrate reduction can reduce α-synuclein aggregation
Once you provide specific hypotheses with supporting evidence, I'll perform the rigorous critical evaluation you're requesting.